Sandra K Knowles

US Patent:

20210380580, Dec 9, 2021

Filed:

Jun 22, 2018

Appl. No.:

16/621953

Inventors:

- Rahway NJ, US
- SHANGHAI, CN
Qiaolin DENG - Princeton NJ, US
Melissa EGBERTSON - Ambler PA, US
Ronald FERGUSON, II - Scotch Plains NJ, US
Xiaolei GAO - Bridgewater NJ, US
Scott Timothy HARRISON - Elkins Park PA, US
Timothy J. HENDERSON - Natick MA, US
Sandra L. KNOWLES - Princeton NJ, US
Chunsing LI - Shanghai, CN
Michael Man-Chu LO - Bedminster NJ, US
Meng NA - Shanghai, CN
Michael T. RUDD - Collegeville PA, US
Oleg B. Selyutin - West Windsor NJ, US
David M. TELLERS - Lansdale PA, US
Ling TONG - Warren NJ, US
Fengqi ZHANG - Edison NJ, US
Takao SUZUKI - Shanghai, CN

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
MSD R&D (CHINA) CO., LTD. - SHANGHAI

International Classification:

C07D 471/04
C07D 401/14
C07D 417/14
C07D 413/14
C07D 487/04
C07D 405/14

Abstract:

The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

US Patent:

20200095261, Mar 26, 2020

Filed:

Dec 18, 2017

Appl. No.:

16/471672

Inventors:

- Rahway NJ, US
Sandra L. KNOWLES - Princeton NJ, US
Chunsing LI - Shanghai, CN
Michael Man-Chu LO - Bedminster NJ, US
Debra L. ONDEYKA - Fanwood NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 498/14
C07D 487/04
C07D 471/04
C07D 513/04
C07D 401/14
C07D 491/048

Abstract:

The present invention is directed to 6,5-fused heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.